A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever

• Robert T. Cartee,

  Roles Writing – original draft

  Affiliation Matrivax Research & Development Corporation, Boston, MA, United States of America

  ⨯
• Ann Thanawastien,

  Roles Writing – review & editing

  Affiliation Matrivax Research & Development Corporation, Boston, MA, United States of America

  ⨯
• Thomas J. Griffin IV,

  Roles Supervision, Writing – review & editing

  Affiliation Matrivax Research & Development Corporation, Boston, MA, United States of America

  ⨯
• John J. Mekalanos,

  Roles Conceptualization, Writing – review & editing

  Affiliation Department of Microbiology, Harvard Medical School, Boston MA, United States of America

  ⨯
• Stephan Bart,

  Roles Investigation, Supervision, Writing – review & editing

  Affiliation Trial Professionals Consulting Group Inc., Woodstock, MD, United States of America

  ⨯
• Kevin P. Killeen

  Roles Conceptualization, Supervision, Writing – review & editing

  * E-mail: kpkilleen@matrivax.com

  Affiliation Matrivax Research & Development Corporation, Boston, MA, United States of America

  http://orcid.org/0000-0001-6313-1081

  ⨯